We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
76
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.91M 0.18%
2,064
+606
+42% +$11.4K
ABT icon
77
Abbott
ABT
$187B
$4.77M 0.18%
112,888
-151,812
-57% -$6.5M
AERI
78
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$4.45M 0.17%
1,180
+506
+75% +$11.2K
CYTR
79
DELISTED
CytRx Corp
CYTR
$4.37M 0.16%
+1,237,464
New +$5.67M
SGYPW
80
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$4.36M 0.16%
+7,912
New +$4.78K
AMRN
81
CALL
Amarin Corp
AMRN
$297M
$4.35M 0.16%
682
+211
+45% +$11.8K
MDCO
82
CALL
DELISTED
Medicines Co
MDCO
$4.34M 0.16%
1,150
-2,464
-68% -$92.9K
LUMO
83
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.34M 0.16%
321
-320
-50% -$31.8K
PBYI icon
84
PUT
Puma Biotechnology
PBYI
$398M
$4.31M 0.16%
+643
New +$32.5K
THC icon
85
PUT
Tenet Healthcare
THC
$22.2B
$3.95M 0.15%
+1,744
New +$45.4K
CELG
86
DELISTED
Celgene Corp
CELG
$3.94M 0.15%
+37,728
New +$4.08M
MNKD icon
87
PUT
MannKind Corp
MNKD
$1.19B
$3.86M 0.14%
12,461
+1,865
+18% +$8.25K
RGNX icon
88
Regenxbio
RGNX
$616M
$3.69M 0.14%
263,177
-148,749
-36% -$1.64M
RGLS
89
CALL
DELISTED
Regulus Therapeutics
RGLS
$3.63M 0.14%
92
-4
-4% -$1.65K
GWPH
90
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.62M 0.14%
273
+101
+59% +$9.65K
PSTV icon
91
Plus Therapeutics
PSTV
$25M
$3.58M 0.13%
9
-1
-10% -$388K
NVO
92
PUT
Novo Nordisk
NVO
$228B
$3.57M 0.13%
+1,718
New +$42.6K
OPGN
93
DELISTED
OpGen, Inc
OPGN
$3.54M 0.13%
22
+6
+38% +$1.12M
TSRO
94
CALL
DELISTED
TESARO, Inc.
TSRO
$3.34M 0.13%
333
-1,825
-85% -$170K
UTHR icon
95
United Therapeutics
UTHR
$26.1B
$3.32M 0.12%
+28,112
New +$3.38M
ZGNX
96
CALL
DELISTED
Zogenix, Inc.
ZGNX
$3.27M 0.12%
1,228
-10,844
-90% -$100K
BIIB icon
97
PUT
Biogen
BIIB
$30.9B
$3.13M 0.12%
100
– –
EIGR
98
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.09M 0.12%
7,693
+1,851
+32% +$945K
ABUS icon
99
Arbutus Biopharma
ABUS
$847M
$3.02M 0.11%
878,531
-297,500
-25% -$1.16M
INDP icon
100
Indaptus Therapeutics
INDP
$243M
$2.9M 0.11%
222
-110
-33% -$1.37M
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.